These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16375767)

  • 1. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.
    Poynard T; Ratziu V; Naveau S; Thabut D; Charlotte F; Messous D; Capron D; Abella A; Massard J; Ngo Y; Munteanu M; Mercadier A; Manns M; Albrecht J
    Comp Hepatol; 2005 Dec; 4():10. PubMed ID: 16375767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
    Poynard T; Lassailly G; Diaz E; Clement K; Caïazzo R; Tordjman J; Munteanu M; Perazzo H; Demol B; Callafe R; Pattou F; Charlotte F; Bedossa P; Mathurin P; Ratziu V;
    PLoS One; 2012; 7(3):e30325. PubMed ID: 22431959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
    Zelber-Sagi S; Webb M; Assy N; Blendis L; Yeshua H; Leshno M; Ratziu V; Halpern Z; Oren R; Santo E
    World J Gastroenterol; 2013 Jan; 19(1):57-64. PubMed ID: 23326163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
    Munteanu M; Tiniakos D; Anstee Q; Charlotte F; Marchesini G; Bugianesi E; Trauner M; Romero Gomez M; Oliveira C; Day C; Dufour JF; Bellentani S; Ngo Y; Traussnig S; Perazzo H; Deckmyn O; Bedossa P; Ratziu V; Poynard T;
    Aliment Pharmacol Ther; 2016 Oct; 44(8):877-89. PubMed ID: 27549244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
    Bril F; McPhaul MJ; Caulfield MP; Castille JM; Poynard T; Soldevila-Pico C; Clark VC; Firpi-Morell RJ; Lai J; Cusi K
    J Investig Med; 2019 Feb; 67(2):303-311. PubMed ID: 30309884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease.
    Thabut D; Naveau S; Charlotte F; Massard J; Ratziu V; Imbert-Bismut F; Cazals-Hatem D; Abella A; Messous D; Beuzen F; Munteanu M; Taieb J; Moreau R; Lebrec D; Poynard T
    J Hepatol; 2006 Jun; 44(6):1175-85. PubMed ID: 16580087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.
    Poynard T; Peta V; Munteanu M; Charlotte F; Ngo Y; Ngo A; Perazzo H; Deckmyn O; Pais R; Mathurin P; Myers R; Loomba R; Ratziu V;
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):393-402. PubMed ID: 30516570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption.
    Imbert-Bismut F; Naveau S; Morra R; Munteanu M; Ratziu V; Abella A; Messous D; Thabut D; Benhamou Y; Poynard T
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):18-27. PubMed ID: 19011575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity.
    Lassailly G; Caiazzo R; Hollebecque A; Buob D; Leteurtre E; Arnalsteen L; Louvet A; Pigeyre M; Raverdy V; Verkindt H; Six MF; Eberle C; Patrice A; Dharancy S; Romon M; Pattou F; Mathurin P
    Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):499-506. PubMed ID: 21499110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibromax and inflamatory markers cannot replace liver biopsy in the evaluation of non-alcoholic fatty liver disease.
    Lardi LL; Lul RM; Port GZ; Coral GP; Peres A; Dornelles GP; Branco F; Fernandes S; Leães CG; Mattos AA; Buss C; Tovo CV
    Minerva Gastroenterol (Torino); 2022 Mar; 68(1):85-90. PubMed ID: 32700499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
    de Lédinghen V; Vergniol J; Foucher J; Merrouche W; le Bail B
    Liver Int; 2012 Jul; 32(6):911-8. PubMed ID: 22672642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease.
    Poynard T; Ratziu V; Charlotte F; Messous D; Munteanu M; Imbert-Bismut F; Massard J; Bonyhay L; Tahiri M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; ;
    BMC Gastroenterol; 2006 Nov; 6():34. PubMed ID: 17096854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
    Guiu B; Crevisy-Girod E; Binquet C; Duvillard L; Masson D; Lepage C; Hamza S; Krausé D; Verges B; Minello A; Cercueil JP; Hillon P; Petit JM
    Eur Radiol; 2012 Apr; 22(4):855-63. PubMed ID: 22101800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
    Perazzo H; Munteanu M; Ngo Y; Lebray P; Seurat N; Rutka F; Couteau M; Jacqueminet S; Giral P; Monneret D; Imbert-Bismut F; Ratziu V; Hartemann-Huertier A; Housset C; Poynard T;
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1081-93. PubMed ID: 25186086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel serum biomarkers modified by the body mass index z-score for the detection of liver fibrosis and steatosis in children with chronic hepatitis C.
    Pokorska-Śpiewak M; Kowalik-Mikołajewska B; Aniszewska M; Pluta M; Marczyńska M
    BMC Infect Dis; 2017 May; 17(1):361. PubMed ID: 28535787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
    Ratziu V; Massard J; Charlotte F; Messous D; Imbert-Bismut F; Bonyhay L; Tahiri M; Munteanu M; Thabut D; Cadranel JF; Le Bail B; de Ledinghen V; Poynard T; ;
    BMC Gastroenterol; 2006 Feb; 6():6. PubMed ID: 16503961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
    Ciećko-Michalska I; Szczepanek M; Wierzbicka-Tutka I; Zahradnik-Bilska J; Mach T
    Arch Med Sci Atheroscler Dis; 2018; 3():e179-e183. PubMed ID: 30775610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease.
    Pais R; Rusu E; Zilisteanu D; Circiumaru A; Micu L; Voiculescu M; Poynard T; Ratziu V
    Eur J Intern Med; 2015 Jan; 26(1):30-6. PubMed ID: 25553983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease.
    Halfon P; Imbert-Bismut F; Messous D; Antoniotti G; Benchetrit D; Cart-Lamy P; Delaporte G; Doutheau D; Klump T; Sala M; Thibaud D; Trepo E; Thabut D; Myers RP; Poynard T
    Comp Hepatol; 2002 Dec; 1(1):3. PubMed ID: 12537583
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women.
    Simental-Mendía LE; Simental-Mendía E; Rodríguez-Hernández H; Rodríguez-Morán M; Guerrero-Romero F
    Ann Hepatol; 2016; 15(5):715-20. PubMed ID: 27493110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.